跳至主要内容
临床试验/NCT01764178
NCT01764178已完成1 期

A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects

JW Pharmaceutical1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2013年1月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
52
试验地点
1
主要终点
Cmax and AUC of study drugs after single oral administration

研究概览

简要总结

The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
20 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male volunteers
  • Age 20-55 years at the time of Screening
  • BMI 19-26 kg/m2 at the time of Screening

排除标准

  • Received other investigational drug within 90 days prior to the first dose of study drug

研究组 & 干预措施

Livalo fixed combination drug

Experimental

Livalo fixed combination drug(Pitavastatin + Valsartan)

干预措施: Livalo fixed combination drug (Drug)

Pitavastatin + Valsartan

Active Comparator

Pitavastatin, Valsartan

干预措施: Pitavastatin, Valsartan (Drug)

结局指标

主要结局

Cmax and AUC of study drugs after single oral administration

时间窗: 0-48hrs

次要结局

  • AUCinf of study drugs after single oral administration(0-48hrs)
  • t1/2β of study drugs after single oral administration(0-48hrs)
  • Tmax of study drugs after single oral administration(0-48hrs)

研究者

发起方
JW Pharmaceutical
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验